Active, not recruitingPhase 2NCT05755997
CERebrolysin In CADASIL
Studying Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ever Neuro Pharma GmbH
- Principal Investigator
- Aleš Tomek, MUDr., Ph.D.Motol University Hospital
- Intervention
- Cerebrolysin(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (1)
- Motol University Hospital, Prague, Czechia
Collaborators
idv Datenanalyse & Versuchsplanung · XClinical GmbH
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05755997 on ClinicalTrials.govOther trials for Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06148051AusCADASIL: An Australian Cohort of CADASILPerminder Sachdev
- RECRUITINGNCT06938100Genotype, Clinical Features and Imaging of Neuroradiological Abnormalities in CADASILFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- RECRUITINGNANCT06935578RAre, But Not aLone: a Large Italian Network to Empower the Impervious diaGNostic Pathway of Rare cerEbrovascular Diseases (ALIGNED)Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- RECRUITINGNCT05072483Natural History Study of CADASILNational Heart, Lung, and Blood Institute (NHLBI)